Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
LMAT's Cash to Debt is ranked higher than
90% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.63 vs. LMAT: No Debt )
Ranked among companies with meaningful Cash to Debt only.
LMAT' s Cash to Debt Range Over the Past 10 Years
Min: 0.43  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.86
LMAT's Equity to Asset is ranked higher than
87% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.61 vs. LMAT: 0.86 )
Ranked among companies with meaningful Equity to Asset only.
LMAT' s Equity to Asset Range Over the Past 10 Years
Min: 0.14  Med: 0.83 Max: 0.89
Current: 0.86
0.14
0.89
F-Score: 7
Z-Score: 16.27
M-Score: -2.59
WACC vs ROIC
6.34%
15.48%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 14.69
LMAT's Operating margin (%) is ranked higher than
77% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.20 vs. LMAT: 14.69 )
Ranked among companies with meaningful Operating margin (%) only.
LMAT' s Operating margin (%) Range Over the Past 10 Years
Min: -10.33  Med: 6.70 Max: 14.69
Current: 14.69
-10.33
14.69
Net-margin (%) 9.90
LMAT's Net-margin (%) is ranked higher than
73% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.71 vs. LMAT: 9.90 )
Ranked among companies with meaningful Net-margin (%) only.
LMAT' s Net-margin (%) Range Over the Past 10 Years
Min: -7.08  Med: 4.13 Max: 10.73
Current: 9.9
-7.08
10.73
ROE (%) 10.82
LMAT's ROE (%) is ranked higher than
68% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.01 vs. LMAT: 10.82 )
Ranked among companies with meaningful ROE (%) only.
LMAT' s ROE (%) Range Over the Past 10 Years
Min: -7.03  Med: 4.50 Max: 11.96
Current: 10.82
-7.03
11.96
ROA (%) 9.20
LMAT's ROA (%) is ranked higher than
80% of the 199 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.86 vs. LMAT: 9.20 )
Ranked among companies with meaningful ROA (%) only.
LMAT' s ROA (%) Range Over the Past 10 Years
Min: -5.75  Med: 3.84 Max: 10.01
Current: 9.2
-5.75
10.01
ROC (Joel Greenblatt) (%) 41.05
LMAT's ROC (Joel Greenblatt) (%) is ranked higher than
81% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.00 vs. LMAT: 41.05 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
LMAT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -24.38  Med: 21.42 Max: 42.55
Current: 41.05
-24.38
42.55
Revenue Growth (3Y)(%) 5.60
LMAT's Revenue Growth (3Y)(%) is ranked higher than
54% of the 155 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. LMAT: 5.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
LMAT' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -4.9  Med: 5.30 Max: 21.4
Current: 5.6
-4.9
21.4
EBITDA Growth (3Y)(%) 26.90
LMAT's EBITDA Growth (3Y)(%) is ranked higher than
83% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.30 vs. LMAT: 26.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
LMAT' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 16.20 Max: 28.3
Current: 26.9
0
28.3
EPS Growth (3Y)(%) 37.20
LMAT's EPS Growth (3Y)(%) is ranked higher than
86% of the 132 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. LMAT: 37.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
LMAT' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -54.3  Med: 18.80 Max: 43.4
Current: 37.2
-54.3
43.4
» LMAT's 10-Y Financials

Financials (Next Earnings Date: 2016-05-02)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

LMAT Guru Trades in Q1 2015

Chuck Royce 9,900 sh (New)
Jim Simons 52,600 sh (+22.15%)
» More
Q2 2015

LMAT Guru Trades in Q2 2015

Jim Simons 75,600 sh (+43.73%)
Chuck Royce 9,900 sh (unchged)
» More
Q3 2015

LMAT Guru Trades in Q3 2015

Jim Simons 116,900 sh (+54.63%)
Chuck Royce 9,900 sh (unchged)
» More
Q4 2015

LMAT Guru Trades in Q4 2015

Jim Simons 123,800 sh (+5.90%)
Chuck Royce Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with LMAT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 39.48
LMAT's P/E(ttm) is ranked lower than
68% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.93 vs. LMAT: 39.48 )
Ranked among companies with meaningful P/E(ttm) only.
LMAT' s P/E(ttm) Range Over the Past 10 Years
Min: 15.99  Med: 34.61 Max: 125
Current: 39.48
15.99
125
Forward P/E 29.67
LMAT's Forward P/E is ranked lower than
89% of the 37 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.08 vs. LMAT: 29.67 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 39.48
LMAT's PE(NRI) is ranked lower than
68% of the 123 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.93 vs. LMAT: 39.48 )
Ranked among companies with meaningful PE(NRI) only.
LMAT' s PE(NRI) Range Over the Past 10 Years
Min: 15.93  Med: 35.03 Max: 125
Current: 39.48
15.93
125
Price/Owner Earnings (ttm) 30.04
LMAT's Price/Owner Earnings (ttm) is ranked lower than
57% of the 79 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.52 vs. LMAT: 30.04 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
LMAT' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 10.44  Med: 48.30 Max: 552.31
Current: 30.04
10.44
552.31
P/B 3.90
LMAT's P/B is ranked lower than
63% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.68 vs. LMAT: 3.90 )
Ranked among companies with meaningful P/B only.
LMAT' s P/B Range Over the Past 10 Years
Min: 0.67  Med: 1.86 Max: 4.06
Current: 3.9
0.67
4.06
P/S 3.84
LMAT's P/S is ranked lower than
64% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.46 vs. LMAT: 3.84 )
Ranked among companies with meaningful P/S only.
LMAT' s P/S Range Over the Past 10 Years
Min: 0.62  Med: 1.75 Max: 4
Current: 3.84
0.62
4
PFCF 33.23
LMAT's PFCF is ranked lower than
60% of the 77 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.13 vs. LMAT: 33.23 )
Ranked among companies with meaningful PFCF only.
LMAT' s PFCF Range Over the Past 10 Years
Min: 9.18  Med: 33.15 Max: 113.97
Current: 33.23
9.18
113.97
POCF 26.57
LMAT's POCF is ranked lower than
78% of the 102 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 15.65 vs. LMAT: 26.57 )
Ranked among companies with meaningful POCF only.
LMAT' s POCF Range Over the Past 10 Years
Min: 8.27  Med: 23.40 Max: 63.61
Current: 26.57
8.27
63.61
EV-to-EBIT 24.12
LMAT's EV-to-EBIT is ranked lower than
60% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.92 vs. LMAT: 24.12 )
Ranked among companies with meaningful EV-to-EBIT only.
LMAT' s EV-to-EBIT Range Over the Past 10 Years
Min: -158.2  Med: 18.45 Max: 60.7
Current: 24.12
-158.2
60.7
EV-to-EBITDA 18.61
LMAT's EV-to-EBITDA is ranked lower than
61% of the 132 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.78 vs. LMAT: 18.61 )
Ranked among companies with meaningful EV-to-EBITDA only.
LMAT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -174.7  Med: 13.10 Max: 2641.2
Current: 18.61
-174.7
2641.2
PEG 2.15
LMAT's PEG is ranked higher than
62% of the 60 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.84 vs. LMAT: 2.15 )
Ranked among companies with meaningful PEG only.
LMAT' s PEG Range Over the Past 10 Years
Min: 1.26  Med: 2.33 Max: 3.72
Current: 2.15
1.26
3.72
Shiller P/E 154.70
LMAT's Shiller P/E is ranked lower than
96% of the 48 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 38.88 vs. LMAT: 154.70 )
Ranked among companies with meaningful Shiller P/E only.
LMAT' s Shiller P/E Range Over the Past 10 Years
Min: 97.29  Med: 126.75 Max: 175.44
Current: 154.7
97.29
175.44
Current Ratio 5.61
LMAT's Current Ratio is ranked higher than
84% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.68 vs. LMAT: 5.61 )
Ranked among companies with meaningful Current Ratio only.
LMAT' s Current Ratio Range Over the Past 10 Years
Min: 2.12  Med: 4.66 Max: 8.11
Current: 5.61
2.12
8.11
Quick Ratio 4.15
LMAT's Quick Ratio is ranked higher than
81% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.70 vs. LMAT: 4.15 )
Ranked among companies with meaningful Quick Ratio only.
LMAT' s Quick Ratio Range Over the Past 10 Years
Min: 1.11  Med: 3.32 Max: 6.98
Current: 4.15
1.11
6.98
Days Inventory 241.69
LMAT's Days Inventory is ranked lower than
85% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 128.91 vs. LMAT: 241.69 )
Ranked among companies with meaningful Days Inventory only.
LMAT' s Days Inventory Range Over the Past 10 Years
Min: 171.21  Med: 217.86 Max: 266.3
Current: 241.69
171.21
266.3
Days Sales Outstanding 55.77
LMAT's Days Sales Outstanding is ranked higher than
65% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 63.39 vs. LMAT: 55.77 )
Ranked among companies with meaningful Days Sales Outstanding only.
LMAT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.34  Med: 55.62 Max: 61.82
Current: 55.77
53.34
61.82
Days Payable 20.61
LMAT's Days Payable is ranked lower than
89% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 56.99 vs. LMAT: 20.61 )
Ranked among companies with meaningful Days Payable only.
LMAT' s Days Payable Range Over the Past 10 Years
Min: 14.93  Med: 23.79 Max: 77.19
Current: 20.61
14.93
77.19

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.00
LMAT's Dividend Yield is ranked lower than
66% of the 141 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.34 vs. LMAT: 1.00 )
Ranked among companies with meaningful Dividend Yield only.
LMAT' s Dividend Yield Range Over the Past 10 Years
Min: 0.28  Med: 1.51 Max: 1.98
Current: 1
0.28
1.98
Dividend Payout 0.38
LMAT's Dividend Payout is ranked higher than
51% of the 90 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.38 vs. LMAT: 0.38 )
Ranked among companies with meaningful Dividend Payout only.
LMAT' s Dividend Payout Range Over the Past 10 Years
Min: 0.38  Med: 0.60 Max: 0.61
Current: 0.38
0.38
0.61
Dividend Growth (3y) 17.00
LMAT's Dividend Growth (3y) is ranked higher than
61% of the 62 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.90 vs. LMAT: 17.00 )
Ranked among companies with meaningful Dividend Growth (3y) only.
LMAT' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 20.5
Current: 17
0
20.5
Forward Dividend Yield 1.09
LMAT's Forward Dividend Yield is ranked lower than
66% of the 132 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.37 vs. LMAT: 1.09 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.00
LMAT's Yield on cost (5-Year) is ranked lower than
74% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.73 vs. LMAT: 1.00 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
LMAT' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.28  Med: 1.51 Max: 1.98
Current: 1
0.28
1.98
3-Year Average Share Buyback Ratio -5.40
LMAT's 3-Year Average Share Buyback Ratio is ranked lower than
61% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.40 vs. LMAT: -5.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
LMAT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -22.6  Med: -4.75 Max: 0.7
Current: -5.4
-22.6
0.7

Valuation & Return

vs
industry
vs
history
Price/Net Cash 20.72
LMAT's Price/Net Cash is ranked lower than
58% of the 52 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.01 vs. LMAT: 20.72 )
Ranked among companies with meaningful Price/Net Cash only.
LMAT' s Price/Net Cash Range Over the Past 10 Years
Min: 2.85  Med: 9.08 Max: 160.2
Current: 20.72
2.85
160.2
Price/Net Current Asset Value 6.69
LMAT's Price/Net Current Asset Value is ranked higher than
53% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.00 vs. LMAT: 6.69 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
LMAT' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.27  Med: 3.14 Max: 6.96
Current: 6.69
1.27
6.96
Price/Tangible Book 5.65
LMAT's Price/Tangible Book is ranked lower than
60% of the 167 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.30 vs. LMAT: 5.65 )
Ranked among companies with meaningful Price/Tangible Book only.
LMAT' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.13  Med: 2.71 Max: 5.88
Current: 5.65
1.13
5.88
Price/Projected FCF 2.98
LMAT's Price/Projected FCF is ranked lower than
69% of the 89 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.93 vs. LMAT: 2.98 )
Ranked among companies with meaningful Price/Projected FCF only.
LMAT' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.51  Med: 1.93 Max: 3.1
Current: 2.98
1.51
3.1
Price/Median PS Value 2.19
LMAT's Price/Median PS Value is ranked lower than
90% of the 163 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.11 vs. LMAT: 2.19 )
Ranked among companies with meaningful Price/Median PS Value only.
LMAT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.42  Med: 0.99 Max: 2.28
Current: 2.19
0.42
2.28
Price/Peter Lynch Fair Value 1.63
LMAT's Price/Peter Lynch Fair Value is ranked higher than
73% of the 51 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.43 vs. LMAT: 1.63 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
LMAT' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 1.7  Med: 2.63 Max: 3.56
Current: 1.63
1.7
3.56
Price/Graham Number 3.13
LMAT's Price/Graham Number is ranked lower than
70% of the 113 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.48 vs. LMAT: 3.13 )
Ranked among companies with meaningful Price/Graham Number only.
LMAT' s Price/Graham Number Range Over the Past 10 Years
Min: 1.52  Med: 2.19 Max: 3.26
Current: 3.13
1.52
3.26
Earnings Yield (Greenblatt) (%) 4.10
LMAT's Earnings Yield (Greenblatt) (%) is ranked higher than
63% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.40 vs. LMAT: 4.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
LMAT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.6  Med: 4.80 Max: 10.9
Current: 4.1
1.6
10.9
Forward Rate of Return (Yacktman) (%) 25.47
LMAT's Forward Rate of Return (Yacktman) (%) is ranked higher than
85% of the 87 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.24 vs. LMAT: 25.47 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
LMAT' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -2.3  Med: 2.40 Max: 26.1
Current: 25.47
-2.3
26.1

More Statistics

Revenue(Mil) $78
EPS $ 0.42
Beta0.60
Short Percentage of Float5.40%
52-Week Range $8.65 - 18.44
Shares Outstanding(Mil)18.34

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 85 92 103
EPS($) 0.48 0.56 0.67
EPS without NRI($) 0.48 0.56 0.67

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:MIL:SFL, TSE:7730, XKRX:041830, NAS:CFMS, NAS:ATRC, ASX:NAN » details
LeMaitre Vascular Inc was incorporated in Massachusetts on November 28, 1983, as Vascutech, Inc. On April 6, 2001, the Company changed its name to LeMaitre Vascular, Inc. The Company is a provider of medical devices and implants for the treatment of peripheral vascular disease. It develops, manufactures, and markets vascular devices to address the needs of vascular surgeons. Its diversified portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart and are well known to vascular surgeons, including the Expandable LeMaitre Valvulotome, the Pruitt F3 Carotid Shunt, VascuTape Radiopaque Tape and the XenoSure biologic patch. Its products are used by vascular surgeons who treat peripheral vascular disease through both open surgical methods and endovascular techniques. In contrast to interventional cardiologists and interventional radiologists, neither of whom are certified to perform open surgical procedures, vascular surgeons can perform both open surgical and minimally invasive endovascular procedures, and are therefore positioned to provide treatment options to patients. The principal product lines include the following: valvulotomes, balloon catheters, carotid shunts, biologic vascular patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy. It has completed fourteen acquisitions of complementary products since 1998. The Company also sells non-vascular medical devices used in general surgery procedures, primarily laparoscopic cholecystectomy. Its leading general surgery product is the Reddick Cholangiogram Catheter, which is used to inject dye into the cystic duct during laparoscopic cholecystectomy. In this procedure, the gall bladder is dissected and removed through small punctures in the abdomen. It also offers two laparoscopic accessories used in laparoscopic gall bladder removal. Notable competitors of the Company include Applied Medical Resources Corporation, Baxter International, Inc., Cardiovascular Systems, Inc., C.R. Bard, Inc., Edwards Lifesciences Corporation, Getinge AB, Jotec GmbH, SAS Perouse Medical, Terumo Medical Corporation, Uresil, LLC, and W. L. Gore & Associates. It relies on a combination of patents, trademarks, trade secret laws, and confidentiality and invention assignment agreements to protect its intellectual property rights. The products are medical devices subject to extensive regulation by the FDA under the Federal Food, Drug, and Cosmetic Act (the FDCA).
» More Articles for LMAT

Headlines

Articles On GuruFocus.com
LeMaitre Vascular Inc. Reports Operating Results (10-Q) Nov 10 2010 
LeMaitre Vascular Inc. Reports Operating Results (10-Q) Aug 12 2010 
LeMaitre Vascular Inc. Reports Operating Results (10-Q) May 13 2010 
LeMaitre Vascular Inc. Reports Operating Results (10-Q) Nov 13 2009 
LeMaitre Vascular Inc. (LMAT) CEO George W Lemaitre buys 1,500 Shares Jun 05 2009 
LeMaitre Vascular Inc. (LMAT) CEO George W Lemaitre buys 1,250 Shares May 28 2009 
LeMaitre Vascular Inc. (LMAT) CEO George W Lemaitre buys 1,000 Shares May 18 2009 
LeMaitre Vascular Inc. Reports Operating Results (10-Q) May 14 2009 

More From Other Websites
LeMaitre Vascular Will Announce First Quarter 2016 Earnings Results on May 2, 2016 Apr 19 2016
LeMaitre Vascular Will Announce First Quarter 2016 Earnings Results on May 2, 2016 Apr 19 2016
LeMaitre Vascular to Participate in the Needham & Company 15th Annual Health Care Conference on... Apr 04 2016
LeMaitre Vascular to Participate in the Needham & Company 15th Annual Health Care Conference on... Apr 04 2016
CryoLife Announces Sale of ProCol® Distribution Rights and Purchase Option to LeMaitre Vascular,... Mar 18 2016
LeMaitre Vascular Acquires ProCol® Vascular Bioprosthesis Mar 18 2016
LEMAITRE VASCULAR INC Financials Mar 16 2016
LEMAITRE VASCULAR INC Files SEC form 10-K, Annual Report Mar 10 2016
LeMaitre Vascular to Participate in the Cowen and Company 36th Annual Health Care Conference on... Mar 04 2016
LeMaitre Vascular Raised to Strong Buy on Solid Q4 Results Mar 02 2016
LeMaitre Vascular to Participate in Two Investor Conferences in March Mar 01 2016
LeMaitre Vascular, Inc. Earnings Analysis: 2015 By the Numbers Feb 29 2016
LeMaitre Vascular Q4 Earnings, Sales Top Estimates; Up Y/Y Feb 26 2016
LEMAITRE VASCULAR INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 24 2016
LeMaitre Q4 2015 Record Sales $20.5mm (+14% organic), Record Net Income $2.5mm (+32%) Feb 24 2016
Q4 2015 LeMaitre Vascular Inc Earnings Release - After Market Close Feb 24 2016
LeMaitre Vascular to Participate in BTIG MedTech Conference February 24-26, 2016 Feb 19 2016
LeMaitre Vascular Will Announce Fourth Quarter 2015 Earnings Results on February 24, 2016 Feb 11 2016
The Zacks Analyst Blog Highlights: LogMeIn, Extreme Networks, INC Research Holdings, Netgear and... Feb 11 2016
Nasdaq Perilously Close to Bear Market: 5 Growth Stocks on Sale Feb 10 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK